according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 16.10.2020 3.3 09.04.2021 23599-00018 Date of first issue: 21.10.2014

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Mometasone Suspension Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Pharmaceutical

stance/Mixture

1.3 Details of the supplier of the safety data sheet

Company : Organon & Co.

30 Hudson Street, 33nd floor

07302 Jersey City, New Jersey, U.S.A

Telephone : 551-430-6000

E-mail address of person responsible for the SDS

EHSSTEWARD@organon.com

1.4 Emergency telephone number

215-631-6999

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Long-term (chronic) aquatic hazard, Category 2 H411: Toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms

Hazard statements : H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P273 Avoid release to the environment.

Response:

P391 Collect spillage.

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 16.10.2020 3.3 09.04.2021 23599-00018 Date of first issue: 21.10.2014

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Mometasone	83919-23-7	Repr. 1B; H360Df STOT RE 2; H373 (Immune system, Liver, Kidney, Skin) Aquatic Chronic 1; H410 M-Factor (Chronic aquatic toxicity): 100	>= 0.025 - < 0.1
Benzalkonium chloride	8001-54-5	Acute Tox. 3; H301 Acute Tox. 2; H330 Acute Tox. 3; H311 Skin Corr. 1; H314 Eye Dam. 1; H318 Aquatic Acute 1; H400 Aquatic Chronic 2; H411 EUH071 M-Factor (Acute aquatic toxicity): 100	>= 0.0025 - < 0.025

For explanation of abbreviations see section 16.

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

Version SDS Number: Date of last issue: 16.10.2020 Revision Date: 3.3 09.04.2021 23599-00018 Date of first issue: 21.10.2014

SECTION 4: First aid measures

4.1 Description of first aid measures

Protection of first-aiders No special precautions are necessary for first aid responders.

If inhaled If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.

Get medical attention if symptoms occur.

In case of eye contact Flush eves with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed If swallowed, DO NOT induce vomiting.

> Get medical attention if symptoms occur. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

None known.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- : Carbon oxides

ucts

5.3 Advice for firefighters

Special protective equipment:

for firefighters

Wear self-contained breathing apparatus for firefighting if nec-

essary. Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 16.10.2020

 3.3
 09.04.2021
 23599-00018
 Date of first issue: 21.10.2014

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g. by containment or oil

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Soak up with inert absorbent material.

For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absor-

bent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Handle in accordance with good industrial hygiene and safety

practice, based on the results of the workplace exposure as-

sessment

Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 16.10.2020

 3.3
 09.04.2021
 23599-00018
 Date of first issue: 21.10.2014

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

Keep in properly labelled containers. Store in accordance with

the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cellulose	9004-34-6	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL
	Further information: Where no specific short-term exposure limit is listed, a figure three times the long-term exposure limit value should be used			
Mometasone	83919-23-7	TWA	1 μg/m3 (OEB 4)	Internal
	Further information: Skin			
		Wipe limit	10 μg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health ef-	Value
			fects	
Glycerine	Workers	Inhalation	Long-term local ef-	56 mg/m3
			fects	
	Consumers	Ingestion	Long-term systemic	229 mg/kg
			effects	bw/day
	Consumers	Inhalation	Long-term local ef-	33 mg/m3
			fects	

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

		<u> </u>
Substance name	Environmental Compartment	Value
Glycerine	Fresh water	0.885 mg/l
	Marine water	0.0885 mg/l
	Intermittent use/release	8.85 mg/l
	Sewage treatment plant	1000 mg/l
	Fresh water sediment	3.3 mg/kg dry
		weight (d.w.)

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 16.10.2020 3.3 09.04.2021 23599-00018 Date of first issue: 21.10.2014

Marine sediment	0.33 mg/kg dry weight (d.w.)
Soil	0.141 mg/kg dry
	weight (d.w.)

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 14387

Filter type : Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : liquid

Colour : white to off-white, opaque

Odour : odourless

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling :

ange

No data available

Flammability (solid, gas) : Not applicable

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 16.10.2020 Date of first issue: 21.10.2014 3.3 09.04.2021 23599-00018

Flammability (liquids) No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower :

flammability limit

No data available

Flash point No data available

Auto-ignition temperature No data available

Decomposition temperature

Decomposition tempera-

ture

No data available

рΗ 4.3 - 4.9

Viscosity

Viscosity, kinematic No data available

Solubility(ies)

Water solubility soluble

Partition coefficient: n-

octanol/water

Not applicable

Vapour pressure No data available

No data available Relative density

Density 1 g/cm³

Relative vapour density No data available

Particle characteristics

Particle size Not applicable

9.2 Other information

Explosives Not explosive

Oxidizing properties The substance or mixture is not classified as oxidizing.

Evaporation rate No data available

Molecular weight Not applicable

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 16.10.2020 3.3 09.04.2021 23599-00018 Date of first issue: 21.10.2014

10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : None known.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact Ingestion

Eye contact

Eye cc

Acute toxicity

Not classified based on available information.

Components:

Mometasone:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

LD50 (Mouse): > 2,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 3.3 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l Exposure time: 4 h

Test atmosphere: dust/mist

Acute toxicity (other routes of :

administration)

LD50 (Rat): 300 mg/kg

Application Route: Subcutaneous Symptoms: Breathing difficulties

Benzalkonium chloride:

Acute oral toxicity : LD50 (Rat): 240 mg/kg

Acute inhalation toxicity : LC50 (Rat, male): > 0.05 - 0.5 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Method: OECD Test Guideline 403

Assessment: Corrosive to the respiratory tract.

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 16.10.2020

 3.3
 09.04.2021
 23599-00018
 Date of first issue: 21.10.2014

Remarks: Based on data from similar materials

Acute dermal toxicity : LD50 (Rat, female): 704 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Mometasone:

Species : Rabbit

Result : No skin irritation

Benzalkonium chloride:

Species : Human

Result : Corrosive after 4 hours or less of exposure

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Mometasone:

Species : Rabbit

Result : No eye irritation

Benzalkonium chloride:

Species : Rabbit

Result : Irreversible effects on the eye

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Mometasone:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Assessment : Does not cause skin sensitisation.

Result : negative

Remarks : The results of a test on guinea pigs showed this substance to

be a weak skin sensitiser.

Benzalkonium chloride:

Test Type : Human repeat insult patch test (HRIPT)

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 16.10.2020

 3.3
 09.04.2021
 23599-00018
 Date of first issue: 21.10.2014

Exposure routes : Skin contact
Species : Humans
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Mometasone:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration Test system: Chinese hamster lung cells

Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells

Result: positive

Test Type: Mouse Lymphoma

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Application Route: Oral Result: negative

Test Type: Chromosomal aberration

Species: Rat

Cell type: Bone marrow

Result: negative

Test Type: unscheduled DNA synthesis assay

Species: Rat Cell type: Liver cells Result: negative

Germ cell mutagenicity- As-

sessment

Weight of evidence does not support classification as a germ

cell mutagen.

Benzalkonium chloride:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Method: OECD Test Guideline 476

Result: negative

Remarks: Based on data from similar materials

Test Type: Chromosome aberration test in vitro

Method: OECD Test Guideline 473

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 16.10.2020 3.3 09.04.2021 23599-00018 Date of first issue: 21.10.2014

Result: negative

Remarks: Based on data from similar materials

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion Method: OECD Test Guideline 474

Result: negative

Remarks: Based on data from similar materials

Carcinogenicity

Not classified based on available information.

Components:

Mometasone:

Species : Rat
Application Route : Inhalation
Exposure time : 2 Years

Dose : 0.067 mg/kg body weight

Result : negative

Species : Mouse
Application Route : Inhalation
Exposure time : 19 Months

Dose : 0.160 mg/kg body weight

Result : negative

Benzalkonium chloride:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years

Method : OECD Test Guideline 453

Result : negative

Remarks : Based on data from similar materials

Species : Mouse
Application Route : Skin contact
Exposure time : 80 weeks
Result : negative

Species : Rabbit
Application Route : Skin contact
Exposure time : 90 weeks
Result : negative

Reproductive toxicity

Not classified based on available information.

Components:

Mometasone:

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 16.10.2020

 3.3
 09.04.2021
 23599-00018
 Date of first issue: 21.10.2014

Effects on fertility : Test Type: Fertility

Species: Rat

Application Route: Subcutaneous

Fertility: NOAEL: 0.015 mg/kg body weight

Symptoms: Reduced embryonic survival, Reduced foetal

weiaht

Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Mouse

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight Result: Embryotoxic effects., Teratogenicity and developmen-

tal toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight

Result: Effects on newborn

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - As-

sessment

Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on

sexual function and fertility, based on animal experiments.

Benzalkonium chloride:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 416

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rabbit

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 16.10.2020 3.3 09.04.2021 23599-00018 Date of first issue: 21.10.2014

Application Route: Ingestion Method: OECD Test Guideline 414

Result: negative

Remarks: Based on data from similar materials

STOT - single exposure

Not classified based on available information.

Components:

Mometasone:

Remarks : Based on available data, the classification criteria are not met.

STOT - repeated exposure

Not classified based on available information.

Components:

Mometasone:

Exposure routes : inhalation (dust/mist/fume)

Target Organs : Immune system, Liver, Kidney, Skin

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Benzalkonium chloride:

Assessment : No significant health effects observed in animals at concentra-

tions of 100 mg/kg bw or less.

Repeated dose toxicity

Components:

Mometasone:

Species : Rat

NOAEL : 0.005 mg/kg
LOAEL : 0.3 mg/kg

Application Route : Oral Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Dog LOAEL : 0.5 mg/kg Application Route : Oral Exposure time : 30 d

Target Organs : Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species : Rat

NOAEL : 0.00013 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 90 d

Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, Liver, thymus gland

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 16.10.2020

 3.3
 09.04.2021
 23599-00018
 Date of first issue: 21.10.2014

Species : Dog

NOAEL : 0.0005 mg/l

Application Route : inhalation (dust/mist/fume)

Exposure time : 90 d

Target Organs : Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow,

Kidney, thymus gland, Liver

Benzalkonium chloride:

Species : Rat

NOAEL : >= 100 mg/kg Application Route : Ingestion Exposure time : 12 Weeks

Aspiration toxicity

Not classified based on available information.

Components:

Mometasone:

Not applicable

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

Mometasone:

Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper res-

piratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

Skin contact : Symptoms: Dermatitis, Itching

Further information

Components:

Mometasone:

Remarks : Dermal absorption possible

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 16.10.2020

 3.3
 09.04.2021
 23599-00018
 Date of first issue: 21.10.2014

SECTION 12: Ecological information

12.1 Toxicity

Components:

Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l

Exposure time: 96 h

Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l

Exposure time: 7 d

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 5 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

EC50 (Americamysis): > 5 mg/l

Exposure time: 96 h

Method: US-EPA OPPTS 850.1035

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to microorganisms : EC50 : > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC: 0.00014 mg/l Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0.34 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

Remarks: No toxicity at the limit of solubility

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 16.10.2020

 3.3
 09.04.2021
 23599-00018
 Date of first issue: 21.10.2014

100

M-Factor (Chronic aquatic

toxicity)

Benzalkonium chloride:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 0.28 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.0056 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

ErC50 (Chlorella pyrenoidosa (aglae)): 0.09 mg/l

Exposure time: 72 h

M-Factor (Acute aquatic tox-

icity)

100

Toxicity to fish (Chronic tox-

icity)

NOEC: 0.032 mg/l Exposure time: 34 d

Species: Pimephales promelas (fathead minnow)

12.2 Persistence and degradability

Components:

Mometasone:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 28 d

Method: OECD Test Guideline 314

Stability in water : Hydrolysis: 50 %(12 d)

Method: OECD Test Guideline 111

Benzalkonium chloride:

Biodegradability : Result: Readily biodegradable.

Method: OECD Test Guideline 301D

Remarks: Based on data from similar materials

12.3 Bioaccumulative potential

Components:

Mometasone:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

Bioconcentration factor (BCF): 107.1 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 4.68

Benzalkonium chloride:

Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 16.10.2020 3.3 09.04.2021 23599-00018 Date of first issue: 21.10.2014

Bioconcentration factor (BCF): < 500

Remarks: Based on data from similar materials

Partition coefficient: noctanol/water : log Pow: 1.692 Remarks: Calculation

12.4 Mobility in soil

Components:

Mometasone:

Distribution among environmental compartments

: log Koc: 4.02

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

ADN : UN 3082

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 16.10.2020 3.3 09.04.2021 23599-00018 Date of first issue: 21.10.2014

 ADR
 : UN 3082

 RID
 : UN 3082

 IMDG
 : UN 3082

 IATA
 : UN 3082

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Mometasone, Benzalkonium chloride)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Mometasone, Benzalkonium chloride)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Mometasone, Benzalkonium chloride)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID,

N.O.S.

(Mometasone, Benzalkonium chloride)

IATA : Environmentally hazardous substance, liquid, n.o.s.

(Mometasone, Benzalkonium chloride)

14.3 Transport hazard class(es)

ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group

ADN

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

ADR

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

Packing group : III
Classification Code : M6
Hazard Identification Number : 90
Labels : 9

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 16.10.2020

 3.3
 09.04.2021
 23599-00018
 Date of first issue: 21.10.2014

IMDG

Packing group : III
Labels : 9
EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 964

aircraft)

Packing instruction (LQ) : Y964
Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen: 964

ger aircraft)

Packing instruction (LQ) : Y964
Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

RID

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII)

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).

: Conditions of restriction for the following entries should be considered: Number on list 3

: Not applicable

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 16.10.2020 3.3 09.04.2021 23599-00018 Date of first issue: 21.10.2014

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

Regulation (EC) No 1005/2009 on substances that de- : Not applicable

plete the ozone layer

Regulation (EU) 2019/1021 on persistent organic pollu- : Not applicable

tants (recast)

Regulation (EC) No 649/2012 of the European Parlia: Not applicable

ment and the Council concerning the export and import

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

Quantity 1 Quantity 2

E2 ENVIRONMENTAL 200 t 500 t

HAZARDS

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H301 : Toxic if swallowed.

H311 : Toxic in contact with skin.

H314 : Causes severe skin burns and eye damage.

H318 : Causes serious eye damage.

H330 : Fatal if inhaled.

H360Df : May damage the unborn child. Suspected of damaging fertili-

ty.

H373 : May cause damage to organs through prolonged or repeated

exposure if inhaled.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.H411 : Toxic to aquatic life with long lasting effects.

EUH071 : Corrosive to the respiratory tract.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Acute : Short-term (acute) aquatic hazard
Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Dam. : Serious eye damage Repr. : Reproductive toxicity

Skin Corr. : Skin corrosion

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 16.10.2020 3.3 09.04.2021 23599-00018 Date of first issue: 21.10.2014

STOT RE : Specific target organ toxicity - repeated exposure

IE OEL : Ireland. List of Chemical Agents and Occupational Exposure

Limit Values - Schedule 1

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN -Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS -Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP -Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL -International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TRGS -Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sheet

Sources of key data used to compile the Safety Data

cy, http://echa.europa.eu/

Classification of the mixture: Classification procedure:

Aquatic Chronic 2 H411 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their

according to Regulation (EC) No. 1907/2006



Mometasone Suspension Formulation

Version Revision Date: SDS Number: Date of last issue: 16.10.2020 3.3 09.04.2021 23599-00018 Date of first issue: 21.10.2014

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN